دورية أكاديمية
812MO Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial.
| العنوان: | 812MO Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial. |
|---|---|
| المؤلفون: | Colombo, N.1 (AUTHOR), Gantzer, J.2 (AUTHOR), Ataseven, B.3 (AUTHOR), Cropet, C.4 (AUTHOR), Scambia, G.5 (AUTHOR), Herrero, A.6 (AUTHOR), Sevelda, P.7 (AUTHOR), Kobayashi, H.8 (AUTHOR), Vuylsteke, P.9 (AUTHOR), Mirza, M.R.10 (AUTHOR), Priou, F.11 (AUTHOR), Buderath, P.12 (AUTHOR), Pisano, C.13 (AUTHOR), Lainez, N.14 (AUTHOR), Guillemet, C.15 (AUTHOR), Burges, A.16 (AUTHOR), Sverdlin, R.17 (AUTHOR), El-Balat, A.18 (AUTHOR), Raban, N.19 (AUTHOR), Ray-Coquard, I.L.20 (AUTHOR) |
| المصدر: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS614-S614. 1p. |
| مصطلحات موضوعية: | *OLAPARIB, *OVARIAN cancer, *BEVACIZUMAB, *DIAGNOSIS |
| قاعدة البيانات: | Academic Search Index |
Full Text Finder | تدمد: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2020.08.951 |